Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting Mar 15, 2022
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update Feb 11, 2022
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells Feb 3, 2022
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma Jan 12, 2022
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference Jan 5, 2022
Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021 Dec 7, 2021
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma Nov 30, 2021
Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual Meeting Nov 18, 2021
